Brown Brothers Harriman & CO Clovis Oncology, Inc. Transaction History

Brown Brothers Harriman & CO

  • $14 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 14, 2018
SELL
$50.12 - $67.72 $3,157 - $4,266
-63 Closed
0 $0
Q4 2017

Feb 14, 2018
BUY
$57.69 - $84.58 $3,634 - $5,328
63
63 $4,000

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0
View Full List

About Clovis Oncology, Inc.

CLVS Quotes by TradingView
  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email